Skip to main content
Quest Diagnostics

Myasthenia gravis

Decades of experience translates into unrivaled expertise interpreting results

Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness that ranges from mild to severe for multiple muscle groups. MG is characterized by mild to severe muscle weakness and most commonly involves acetylcholine receptor (AChR) antibodies.

Detection of 5 known antibodies can help guide treatment options

A misdiagnosis is more likely when not screening for LRP4 antibodies 

Our comprehensive myasthenia gravis portfolio includes testing for LRP4 antibodies.
 
  • LRP4 antibodies are believed to be the third-leading cause of MG6
  • Most LRP4-positive patients improve after standard MG therapy4
  • LRP4 is most prevalent in ocular MG7

Why order myasthenia gravis testing from Quest

Comprehensive portfolio tests for 5 known antibodies (AChR, MuSK, LRP4, RyR, and Titin)

Decades of experience translates into unrivaled expertise interpreting results
Our comprehensive MG portfolio tests for AChR, MuSK, LRP4, RyR, and Titin
Test name
Myasthenia Gravis Panel 2 with Reflex to MuSK Antibody AChR Binding, Blocking, Modulating Antibody
Acetylcholine Receptor Binding Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
LRP4 Autoantibody Test
MuSK and LRP4 Antibodies Panel
MuSK Antibody Test
RyR Autoantibody Test
Striated Muscle Antibody with Reflex to Titer
Titin Autoantibody Test
Myasthenia Gravis Panel 1 AChR Binding, Anti-Striated Muscle Antibody with Reflex
Myasthenia Gravis Panel 2 AChR Binding, Blocking, Modulating Antibody
Myasthenia Gravis Panel 3 AChR Binding, Blocking, Modulating Antibody, Anti-Striated Muscle Antibody with Reflex

References

1. Rivner MH, Pasnoor M, Dimachkie MM, et al. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018;36(2):293-310. doi:10.1016/j.ncl.2018.01.004

2. Suzuki S, Utsugisawa K, Nagane Y, et al. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis. 2011;740583. doi:10.4061/2011/740583

3. Haven TR, Astill ME, Pasi BM, et al. An algorithm for acetylcholine receptor antibody testing in patients with suspected myasthenia gravis. Clin Chem.

2010;56(6):1028-1029. doi:10.1373/clinchem.2009.140392

4. Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62(3):333-343. doi:10.1002/mus.26985

5. Antibodies.com.Titin antibodies. Accessed August 27, 2020. https://www.antibodies.com/products/primary-antibodies/target=Titin

6. Zouvelou V, Zisimopoulou P, Rentzos M, et al. Double seronegative myasthenia gravis with anti-LRP4 antibodies. Neuromuscul Disord. 2013;23(7):568-570. doi:10.1016/j.nmd.2013.03.013

7. Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5(F1000 Faculty Rev):1513. doi:10.12688/f1000research.8206.1

Join our email community

Get the very latest news and information from Quest Advanced® Neurology.

Sign up

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.